Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant
Therapeutics? innovative immune modulating regulatory T cell therapy platform. By combining their strengths,
the companies are set to explore new frontiers in enabling allogeneic tissue transplant with a focus on enhanced
patient outcomes and improved quality of life. The upcoming Phase 2 trial builds upon the promising results
from a Phase 1 study which demonstrated an excellent safety profile and encouraging efficacy signals with
TRACT?s autologous Treg product, TregCelTM.